본문으로 바로가기
현재 위치:
Home
진료과
종양내과
이경은
관심콘텐츠
프린트

의료진 소개

진료과 의료진
이경은 의사

이경은 교수


종양내과, 유방암센터 관심의료진 등록

전문 진료 분야

유방암(임상시험포함)

진료 일정

진료예약 간편 예약 고맙습니다

학력 및 경력사항

학력사항

  • 서울대학교 의과대학 박사
  • 이화여자대학교 의과대학 석사
  • 이화여자대학교 의과대학 졸업

교육 및 연구경력

  • 2003-현재  | 이대목동병원 혈액종양내과 교수
  • 2010-2011  | Post doctoral fellowship, Mount Sinai Medical School, NY, US
  • 2003  | 한림의대 강남성심병원 혈액종양내과 조교수
  • 2002-2003  | 삼성서울병원 혈액종양내과 전임의
  • 2001-2002  | 이대목동병원 혈액종양내과 전임의
  • 2006-2001  | 이화여자대학교 부속병원 인턴, 내과 전공의

수상경력

  • 2002 | ASCO(미국임상종양학회) Merit Award

기타 학술 관련 경력

  • 2022-현재  | 대한암학회 상임이사, 정회원
  • 2022-현재  | 대한종양내과학회 상임이사, 정회원
  • 대한내과학회 정회원
  • Member of European Society of Medical Oncology (ESMO)
  • Member of American Society of Clinical Oncology (ASCO)
  • Member of Korean Cancer Association
  • Member of Korean Internal Medicine
  • Member of Korean Medical Association
  • 2002  | American Society of Clinical Oncology meeting, Merit Award

논문

  •  Comparison of Treatment Patterns and Clinical Outcomes by Gender in Locally Advanced Head and Neck Squamous Cell Carcinoma (KCSG HN13-01).  CANCERS. 2023, v.15 no.2, 471. 
  •  Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: The Concept of Chemo-Selection (KCSG HN13-01).  CANCER RESEARCH AND TREATMENT. 2022, v.54 no.1, 109-117. 
  •  Data collection framework for electronic medical record-based real-world data to evaluate the effectiveness and safety of cancer drugs: a nationwide real-world study of the Korean Cancer Study Group.  Ther Adv Med Oncol . 2022-11. 
  •  Phase II study to investigate the efficacy of trastuzumab biosimilar (Herzuma®) plus treatment of physician’s choice (TPC) in patients with heavily pretreated HER-2+ metastatic breast cancer (KCSG BR 18–14/ KM10B).  The Breast . 2022-10. 
  •  β catenin blockers enhance the effect of CDK4/6 inhibitors on stemness and proliferation suppression in endocrine resistant breast cancer cells.  Oncol Rep. 2022-07. 
  •  Comparative analysis of cancer gene mutations using targeted sequencing in matched primary and recurrent gastric cancers after chemotherapy.  Genes Genomics. 2022-05. 
  •  Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09).  Cancer Res Treat. 2022-03. 
  •  Characteristics and treatment patterns in older patients with locally advanced head and neck cancer (KCSG HN13-01).  Korean J Intern Med. 2022-01. 
  •  Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.  Cancer Res Treat. 2021-07. 
  •  Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10).  Cancers (Basel). 2021-06. 
  •  Induction Chemotherapy as a Prognostication Index and Guidance for Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma: the Concept of Chemo-Selection (KCSG HN13-01).  Cancer Res Treat. 2021-04. 
  •  Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13).  Cytokine . 2021-04. 
  •  Hyperprogressive disease and its clinical impact in patients with recurrent and/or metastatic head and neck squamous cell carcinoma treated with immune-checkpoint inhibitors: Korean cancer study group HN 18-12.  J Cancer Res Clin Oncol. 2020-12. 
  •  Palbociclib Plus Exemestane With Gonadotropin-Releasing Hormone Agonist Versus Capecitabine in Premenopausal Women With Hormone Receptor-Positive, HER2-negative Metastatic Breast Cancer (KCSG-BR15-10): A Multicentre, Open-Label, Randomised, Phase 2 Trial.  Lancet Oncol . 2019-12. 
  •  Tumor genomic profiling guides metastatic gastric cancer patients to targeted treatment: The VIKTORY Umbrella Trial.  Cancer Discov. 2019-07.